Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monthly OCT Monitoring of Ozurdex for Macular Oedema Related to Retinal Vascular Diseases
2010-023110-30Phase 4Completed
- Sponsor
- King's College Hospital
- Start
- Dec 2010
- Modality
- Small Molecules, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozurdex in macular edema secondary to retinal vascular disease (ME-RVD) and macular edema, sponsored by King's College Hospital. Primary endpoint: Mean change in OCT at 4 weekly time points. Started Dec 2010; status: completed.
02
Drugs
ozurdex
03
Conditions
macular edema secondary to retinal vascular disease (ME-RVD)macular edema
Beyond the preview
Go deeper on 2010-023110-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023110-30.